Derleme
BibTex RIS Kaynak Göster
Yıl 2019, Cilt: 1 Sayı: 3, 105 - 110, 23.12.2019

Öz

Kaynakça

  • REFERENCES1. Light RW, MacGregor MI, Luchsinger PC, Ball WC. Pleural effusions: the diagnostic seperation of transudates and exudates. Ann Inter Med 1972;77:507-13.2. Romero S, Candela A, Marti’n C, Hernandez L, Trigo C, Gil J. Evaluation of different criteria fort he separation of pleural transudates from exudates. Chest 1993;104:399-404.3. Vives M, Porcel M, Vincent de Vera MC, Ribelles R, Rubio M. A study of Light’s criteria and possible modifications for distinguishing exudative from transudative pleural effusions. Chest 1996;109:1503-7.4. Kopcinovic LM, Culej J. Pleural, peritoneal and pericardial effusions a biochemical approach. Biochemia Medica 2014;24(1):123-37.5. Hassan T, Al-Alawi M, Chotirmall SH, McElvaney NG. Pleural fluid analysis: standstill or a work in progress? Pulm Med Hindawi 2012 (article ID 716235).6. Bielsa S, Porcel JM, Castellote J, Mas E, Esquerda A, Light RW. Solving the Light’s criteria misclassification rate of cardiac and hepatic transudates. Respirology 2012;17:721-6.7. Romero-Candeira S, Fernandez C, Martin C, Sanchez-Paya J, Hernandez L. Influence of diuretics on the concentration of proteins and other components of pleural transudates in patients with heart failure. Am J Med 2001;110:681-6.8. Romero-Candeira S, Hernandez L, Romero-Brufao S, Orts D, Fernandez C, Martin C. Is it meaningful to use biochemical parameters to discriminate between transudative and exudative pleural effusions? Chest 2002;122:1524-9.9. Romero-Candeira S, Hernandez L. The separation of transudates and exudates with particular reference to the protein gradient. Opin Pulm Med 2004;10:283-7.10. Light RW. Pleural Diseases. Sixth edition. Philadelphia-USA: Lippincott Williams and Wilkins, a Wolters Kluwer business; 2013:p.86-127.11. Light RW, Ball WC. Lactate dehydrogenase isoenzymes in pleural effusions. Am Rev Respir Dis 1973;108:660-4.12. Heffner JE, Brown LK, Barbieri CA. Diagnostic value of tests that discriminate between exudative and transudative pleural effusions. Chest 1997;111:970-80.13. Hamm H, Brohan U, Bohmer R, Missmahl HP. Cholesterol in pleural effusions. Chest 1987;92:296-302.14. Burgess LJ, Maritz FJ, Frans Taljaard JJ. Comparative analysis of the biochemical parameters used to distinguish between pleural transudates and exudates. Chest 1995;107:1604-9.15. Hamel AB, Yorgi KN, Bam N, Das SK, Karn R. Pleural fluid cholesterol in differantiating exudative and transudative pleural effusion. Pulm Med Hindawi 2013 article ID 135036.16. Wilcox ME, Chong CAKY, Stanbrook MB, Tricco AC, Wong C, Straus SE. Does this patient have an exudative pleural effusion? The rational clinical examination systematic review. JAMA 2014;311(23):2422-31.17. Henry NL, Hayes DF. Cancer biomarkers. Mol Oncol 2012;6:140-6.18. Porcel JM. Pleural effusions from congestive heart failure. Semin Respir Crit Care Med 2010;31689-697.19. Roth BJ, O’Meara TF, Hal Cragun W. The serum-effusion albumin gradient in the evaluation of pleural effusions. Chest 1990;98:546-9.20. Tarn AC, Lapworth R. Biochemical analysis of pleural fluid: what should we measure? Ann Clin Biochem 2001;38:311-22.21. Porcel JM. Utilization of BNP and NT-proBNP in the diagnosis of pleural effusions due to heart failure. Curr Opin Pulm Med 2011;17:215-9.22. Mohammed AA, Januzzi JL. Natriuretic peptides in the diagnosis and management of acute heart failure. Heart Fail Clin 2009;5:489-500.23. Porcel JM, Vives M, Cao G, Esquerda A, Rubio M, Rivas MC. Measurement of pro-brain nacriuretic peptide in pleural fluid for the diagnosis of pleural effusions due to heart failure. Am J Med 2004;116:417-20.24. Zhaou Q, Ye ZJ, Su Y, Zhang JC, Shi HZ. Diagnostic value of N-terminal pro-brain natriuretic peptide for pleural effusion due to heart failure: a meta-analysis. Heart 2010;95(15):1207-11.25. Yorgancioglu A, Alpaydin AO, Yaman N, Taneli F, Bayturan O, Cosgun AS ve ark. Serum and pleural fluid N-terminal-pro-B type natriuretic peptide concentrations in the differantial diagnosis of pleural effusions. Tuberk Toraks 2011;59(1):1-7.26. Cincin A, Abul Y, Ozben B, Tanrikulu A, Topaloglu N, Ozgul G, et al. Pleural fluid amino-terminal brain natriuretic peptide in patients with pleural effusions. Respir Care 2013;58(2):313-9.27. Liao H, Na MJ, Dikensoy O, Lane KB, Randal B, Light RW. The diagnostic value of pleural fluid NT-pro-BNP levels in patients with cardiovascular diseases. Respirology 2008;13:53-7.28. Seyhan EC, Altin S, Cetinkaya E, Sokucu S, Gunluoglu MZ, Demir A, et al. The importance of pleural fluid and serum NT-proBNP levels in differentiating pleural effusion due to heart failure from other causes of effusion. Intern Med 2009;48(5):287-93.29. Bayram M, Ozkan G, Oztekin E, Bakan ND, Acikmese B, Bes S, et al. Role of serum and pleural fluid NT-proBNP levels in identifying pleural effusion due to heart failure. Multidisciplinary Respiratory Medicine 2009;4(3):175-181.30. Janda S and Swiston J. Diagnostic accuracy of pleural fluid NT-pro-BNP for pleural effusions of cardiac origin: systematic review and meta-analysis. BMC Pulmonary Medicine 2010;10:58.31. Porcel JM, Chorda J, Cao G, Esquerda A, Ruiz-Gonzalez A, Vives M. Comparing serum and pleural fluid pro-brain natriuretic peptide (NT-proBNP) levels with pleural-to-serum albumin gradient fort he identification of cardiac effusions misclassified by Light’s criteria. Respirology 2007;12(5):654-9.32. Tomcsanyi J, Nagy E, Somloi M, Moldvay J, Bezzegh A, Bozsik B, et al. NT-brain natriuretic peptide levels in pleural fluid distinguish between pleural effusions due to heart failure. Am J Med 2004;116(6):417-20.33. Kolditz M, Halank M, Schiemanck S, Schmeisser A, Höffken G. High diagnostic accuracy of NT-pro-BNP for cardiac origin of pleural effusions. Eur Respir J 2006;28:144-50.34. Porcel JM, Martinez-Alonso M, Cao G, Bielsa S, Sopena A, Esquerda A. Biomarkers of heart failure in pleural fluid. Chest 2009;136(3):671-7.35. Long AC, O’Neal HR, Peng S, Lane KB, Light RW. Comparison of pleural fluid N-terminal pro-brain natriuretic peptide and brain natriuretic-32 peptide levels. Chest 2010;137(6):1369-74.36. Marinho FC, Vargas FS, Fabri J, Acencio M, Genofre EH, Antonangelo L, et al. Clinical usefulness of B-type natriuretic peptide in the diagnosis of pleural effusions due to heart failure. Respirology 2011;16(3):495-9.37. Porcel JM, Bielsa S, Morales-Rull JL, Civit C, Cao G, Light RW, et al. Comparison of pleural fluid NT-proBNP, MR-proANP and MR-proADM fort he diagnosis of cardiac effusions. Respirology 2013;18:540-5.38. Ozsu S, Gulsoy A, Karahan SC, Mentese A, Nuhoglu I, Ozlu T. Diagnostic value of pleural effusion ischaemia-modified albumin in patients with cardiac failure. Ann Clin Biochem 2011;48:45-50.39. Dikensoy O, Celik N, Kul S, Gogebakan B, Bayram H, Light RW. Ischemia modified albumin in the differential diagnosis of pleural effusions. Respir Med 2011;105(11):1712-7.40. Ozsu S, Oztuna F, Mentese A, Abul Y, Ozlu T. Diagnostic value of suPAR in differentiating noncardiac pleural effusions from cardiac pleural effusions. Clin Respir 2016;10(1):61-6.

THE NEW BIOMARKERS USED IN THE DIFFERENTIATION BETWEEN TRANSUDATE AND EXUDATE PLEURAL EFFUSIONS

Yıl 2019, Cilt: 1 Sayı: 3, 105 - 110, 23.12.2019

Öz

Etiological
diagnosis of pleural effusion is sometimes easy and sometimes very difficult
challenge. In most of patients with pleural effusion, the symptoms, signs and
laboratory data are not pathognomonic for etiologic diagnosis.  In a patient with an undiagnosed pleural
effusion, the first question to answer is whether the fluid is a transudate or
an exudate. This is usually determined by means of Light's criteria. In
patients under diuretic treatment, Light's criteria misclassify transudates as
exudates, but the pleural fluid NT-pro-BNP levels usually is above 1500 pg/mL
in pleural effusions associated with heart failure.

Kaynakça

  • REFERENCES1. Light RW, MacGregor MI, Luchsinger PC, Ball WC. Pleural effusions: the diagnostic seperation of transudates and exudates. Ann Inter Med 1972;77:507-13.2. Romero S, Candela A, Marti’n C, Hernandez L, Trigo C, Gil J. Evaluation of different criteria fort he separation of pleural transudates from exudates. Chest 1993;104:399-404.3. Vives M, Porcel M, Vincent de Vera MC, Ribelles R, Rubio M. A study of Light’s criteria and possible modifications for distinguishing exudative from transudative pleural effusions. Chest 1996;109:1503-7.4. Kopcinovic LM, Culej J. Pleural, peritoneal and pericardial effusions a biochemical approach. Biochemia Medica 2014;24(1):123-37.5. Hassan T, Al-Alawi M, Chotirmall SH, McElvaney NG. Pleural fluid analysis: standstill or a work in progress? Pulm Med Hindawi 2012 (article ID 716235).6. Bielsa S, Porcel JM, Castellote J, Mas E, Esquerda A, Light RW. Solving the Light’s criteria misclassification rate of cardiac and hepatic transudates. Respirology 2012;17:721-6.7. Romero-Candeira S, Fernandez C, Martin C, Sanchez-Paya J, Hernandez L. Influence of diuretics on the concentration of proteins and other components of pleural transudates in patients with heart failure. Am J Med 2001;110:681-6.8. Romero-Candeira S, Hernandez L, Romero-Brufao S, Orts D, Fernandez C, Martin C. Is it meaningful to use biochemical parameters to discriminate between transudative and exudative pleural effusions? Chest 2002;122:1524-9.9. Romero-Candeira S, Hernandez L. The separation of transudates and exudates with particular reference to the protein gradient. Opin Pulm Med 2004;10:283-7.10. Light RW. Pleural Diseases. Sixth edition. Philadelphia-USA: Lippincott Williams and Wilkins, a Wolters Kluwer business; 2013:p.86-127.11. Light RW, Ball WC. Lactate dehydrogenase isoenzymes in pleural effusions. Am Rev Respir Dis 1973;108:660-4.12. Heffner JE, Brown LK, Barbieri CA. Diagnostic value of tests that discriminate between exudative and transudative pleural effusions. Chest 1997;111:970-80.13. Hamm H, Brohan U, Bohmer R, Missmahl HP. Cholesterol in pleural effusions. Chest 1987;92:296-302.14. Burgess LJ, Maritz FJ, Frans Taljaard JJ. Comparative analysis of the biochemical parameters used to distinguish between pleural transudates and exudates. Chest 1995;107:1604-9.15. Hamel AB, Yorgi KN, Bam N, Das SK, Karn R. Pleural fluid cholesterol in differantiating exudative and transudative pleural effusion. Pulm Med Hindawi 2013 article ID 135036.16. Wilcox ME, Chong CAKY, Stanbrook MB, Tricco AC, Wong C, Straus SE. Does this patient have an exudative pleural effusion? The rational clinical examination systematic review. JAMA 2014;311(23):2422-31.17. Henry NL, Hayes DF. Cancer biomarkers. Mol Oncol 2012;6:140-6.18. Porcel JM. Pleural effusions from congestive heart failure. Semin Respir Crit Care Med 2010;31689-697.19. Roth BJ, O’Meara TF, Hal Cragun W. The serum-effusion albumin gradient in the evaluation of pleural effusions. Chest 1990;98:546-9.20. Tarn AC, Lapworth R. Biochemical analysis of pleural fluid: what should we measure? Ann Clin Biochem 2001;38:311-22.21. Porcel JM. Utilization of BNP and NT-proBNP in the diagnosis of pleural effusions due to heart failure. Curr Opin Pulm Med 2011;17:215-9.22. Mohammed AA, Januzzi JL. Natriuretic peptides in the diagnosis and management of acute heart failure. Heart Fail Clin 2009;5:489-500.23. Porcel JM, Vives M, Cao G, Esquerda A, Rubio M, Rivas MC. Measurement of pro-brain nacriuretic peptide in pleural fluid for the diagnosis of pleural effusions due to heart failure. Am J Med 2004;116:417-20.24. Zhaou Q, Ye ZJ, Su Y, Zhang JC, Shi HZ. Diagnostic value of N-terminal pro-brain natriuretic peptide for pleural effusion due to heart failure: a meta-analysis. Heart 2010;95(15):1207-11.25. Yorgancioglu A, Alpaydin AO, Yaman N, Taneli F, Bayturan O, Cosgun AS ve ark. Serum and pleural fluid N-terminal-pro-B type natriuretic peptide concentrations in the differantial diagnosis of pleural effusions. Tuberk Toraks 2011;59(1):1-7.26. Cincin A, Abul Y, Ozben B, Tanrikulu A, Topaloglu N, Ozgul G, et al. Pleural fluid amino-terminal brain natriuretic peptide in patients with pleural effusions. Respir Care 2013;58(2):313-9.27. Liao H, Na MJ, Dikensoy O, Lane KB, Randal B, Light RW. The diagnostic value of pleural fluid NT-pro-BNP levels in patients with cardiovascular diseases. Respirology 2008;13:53-7.28. Seyhan EC, Altin S, Cetinkaya E, Sokucu S, Gunluoglu MZ, Demir A, et al. The importance of pleural fluid and serum NT-proBNP levels in differentiating pleural effusion due to heart failure from other causes of effusion. Intern Med 2009;48(5):287-93.29. Bayram M, Ozkan G, Oztekin E, Bakan ND, Acikmese B, Bes S, et al. Role of serum and pleural fluid NT-proBNP levels in identifying pleural effusion due to heart failure. Multidisciplinary Respiratory Medicine 2009;4(3):175-181.30. Janda S and Swiston J. Diagnostic accuracy of pleural fluid NT-pro-BNP for pleural effusions of cardiac origin: systematic review and meta-analysis. BMC Pulmonary Medicine 2010;10:58.31. Porcel JM, Chorda J, Cao G, Esquerda A, Ruiz-Gonzalez A, Vives M. Comparing serum and pleural fluid pro-brain natriuretic peptide (NT-proBNP) levels with pleural-to-serum albumin gradient fort he identification of cardiac effusions misclassified by Light’s criteria. Respirology 2007;12(5):654-9.32. Tomcsanyi J, Nagy E, Somloi M, Moldvay J, Bezzegh A, Bozsik B, et al. NT-brain natriuretic peptide levels in pleural fluid distinguish between pleural effusions due to heart failure. Am J Med 2004;116(6):417-20.33. Kolditz M, Halank M, Schiemanck S, Schmeisser A, Höffken G. High diagnostic accuracy of NT-pro-BNP for cardiac origin of pleural effusions. Eur Respir J 2006;28:144-50.34. Porcel JM, Martinez-Alonso M, Cao G, Bielsa S, Sopena A, Esquerda A. Biomarkers of heart failure in pleural fluid. Chest 2009;136(3):671-7.35. Long AC, O’Neal HR, Peng S, Lane KB, Light RW. Comparison of pleural fluid N-terminal pro-brain natriuretic peptide and brain natriuretic-32 peptide levels. Chest 2010;137(6):1369-74.36. Marinho FC, Vargas FS, Fabri J, Acencio M, Genofre EH, Antonangelo L, et al. Clinical usefulness of B-type natriuretic peptide in the diagnosis of pleural effusions due to heart failure. Respirology 2011;16(3):495-9.37. Porcel JM, Bielsa S, Morales-Rull JL, Civit C, Cao G, Light RW, et al. Comparison of pleural fluid NT-proBNP, MR-proANP and MR-proADM fort he diagnosis of cardiac effusions. Respirology 2013;18:540-5.38. Ozsu S, Gulsoy A, Karahan SC, Mentese A, Nuhoglu I, Ozlu T. Diagnostic value of pleural effusion ischaemia-modified albumin in patients with cardiac failure. Ann Clin Biochem 2011;48:45-50.39. Dikensoy O, Celik N, Kul S, Gogebakan B, Bayram H, Light RW. Ischemia modified albumin in the differential diagnosis of pleural effusions. Respir Med 2011;105(11):1712-7.40. Ozsu S, Oztuna F, Mentese A, Abul Y, Ozlu T. Diagnostic value of suPAR in differentiating noncardiac pleural effusions from cardiac pleural effusions. Clin Respir 2016;10(1):61-6.
Toplam 1 adet kaynakça vardır.

Ayrıntılar

Birincil Dil İngilizce
Konular Yoğun Bakım
Bölüm Original Articles
Yazarlar

Turgut Teke

Kerim Yesildag

Yayımlanma Tarihi 23 Aralık 2019
Gönderilme Tarihi 16 Eylül 2019
Kabul Tarihi 5 Kasım 2019
Yayımlandığı Sayı Yıl 2019 Cilt: 1 Sayı: 3

Kaynak Göster

APA Teke, T., & Yesildag, K. (2019). THE NEW BIOMARKERS USED IN THE DIFFERENTIATION BETWEEN TRANSUDATE AND EXUDATE PLEURAL EFFUSIONS. Eurasian Journal of Critical Care, 1(3), 105-110.
AMA Teke T, Yesildag K. THE NEW BIOMARKERS USED IN THE DIFFERENTIATION BETWEEN TRANSUDATE AND EXUDATE PLEURAL EFFUSIONS. Eurasian j Crit Care. Aralık 2019;1(3):105-110.
Chicago Teke, Turgut, ve Kerim Yesildag. “THE NEW BIOMARKERS USED IN THE DIFFERENTIATION BETWEEN TRANSUDATE AND EXUDATE PLEURAL EFFUSIONS”. Eurasian Journal of Critical Care 1, sy. 3 (Aralık 2019): 105-10.
EndNote Teke T, Yesildag K (01 Aralık 2019) THE NEW BIOMARKERS USED IN THE DIFFERENTIATION BETWEEN TRANSUDATE AND EXUDATE PLEURAL EFFUSIONS. Eurasian Journal of Critical Care 1 3 105–110.
IEEE T. Teke ve K. Yesildag, “THE NEW BIOMARKERS USED IN THE DIFFERENTIATION BETWEEN TRANSUDATE AND EXUDATE PLEURAL EFFUSIONS”, Eurasian j Crit Care, c. 1, sy. 3, ss. 105–110, 2019.
ISNAD Teke, Turgut - Yesildag, Kerim. “THE NEW BIOMARKERS USED IN THE DIFFERENTIATION BETWEEN TRANSUDATE AND EXUDATE PLEURAL EFFUSIONS”. Eurasian Journal of Critical Care 1/3 (Aralık 2019), 105-110.
JAMA Teke T, Yesildag K. THE NEW BIOMARKERS USED IN THE DIFFERENTIATION BETWEEN TRANSUDATE AND EXUDATE PLEURAL EFFUSIONS. Eurasian j Crit Care. 2019;1:105–110.
MLA Teke, Turgut ve Kerim Yesildag. “THE NEW BIOMARKERS USED IN THE DIFFERENTIATION BETWEEN TRANSUDATE AND EXUDATE PLEURAL EFFUSIONS”. Eurasian Journal of Critical Care, c. 1, sy. 3, 2019, ss. 105-10.
Vancouver Teke T, Yesildag K. THE NEW BIOMARKERS USED IN THE DIFFERENTIATION BETWEEN TRANSUDATE AND EXUDATE PLEURAL EFFUSIONS. Eurasian j Crit Care. 2019;1(3):105-10.

Indexing and Abstracting

1493315074 2096820551208572097121274